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Abstract 
Generic topical ophthalmic medications are poorly regulated by the Food and Drug 
Administration, resulting in an uncertainty of generics' efficacy and safety and unnecessarily 
placing patients at risk. In 1999, more than 200 documented cases of corneal damage as severe 
as corneal melting were linked to the use of a generic formulation of diclofenac, which was 
consequently pulled from the market. These devastating iatrogenic effects demonstrate the 
need for stricter testing of generic ophthalmic drugs prior to reaching the public. This report 
addresses this urgent need by proposing an in vitro model for simultaneously predicting corneal 
penetration and epithelial toxicity of topical ophthalmic formulations. Penetration and safety of 
ophthalmic medications have been studied separately, but until now, the development of an 
assay to accurately predict both penetration and safety in parallel has been overlooked. In this 
report, recent and ongoing research will be reviewed to (1) elucidate the complexities of 
corneal penetration and the effects of topical ophthalmic formulations on corneal penetration, 
and (2) identify important characteristics of existing models to incorporate in the proposed in 
vitro penetration and safety assay. Critical features of the model proposed here include a 
trephinated porcine cornea from tissue discards affixed in a Franz diffusion cell, permitting 
concurrent drug penetration and epithelial health monitoring. A robust, cost-effective 
penetration and safety assay such as this would provide drug companies with a valuable tool to 
eliminate chances of future iatrogenic effects due to topical ophthalmic drugs. 
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Introduction 
Ten years ago, more than 200 cases of severe corneal damage, ranging from epithelial 
sloughing to full-blown corneal melting, were linked to the use of a generic topical ophthalmic 
drug, diclofenac (Flach, 2000; Congdon et al., 2001). Similar iatrogenic corneal events have also 
been reported, in addition to cases of diminished efficacy due to generic formulations (Jackson, 
2010). These incidents highlight a major flaw in the regulation and testing of generic ophthalmic 
drugs by the Food and Drug Administration {FDA) and drug companies, respectively, which 
allows topical ophthalmic generic medications to be sold with limited screening. Specifically, 
inactive additives in topical ophthalmic formulations, which have been shown to vastly alter 
corneal permeability and epithelial integrity, are not strictly regulated. This significant 
deficiency lies in that the FDA does not require drug companies to demonstrate bioequivalence 
(absorption rates) or therapeutic equivalence {pharmacological effects) of a new generic 
ophthalmic formulation to the original innovator drug (Jackson, 2010). This regulatory hole is a 
serious problem that increasingly places patients' health at risk as more and more ophthalmic 
drugs come off patent protection and new generic formulations come to market in the next 
decade. Drug companies manufacturing and selling generic drugs are under extreme pressure 
to keep costs low to be competitive, so research and development of generic drug formulations 
will rarely exceed that which is required by the FDA. Therefore, lenient FDA regulations and 
inadequate drug company screening are significant impediments to ensuring generic efficacy 
and safety. To make generic ophthalmic drugs safer, a significant paradigm shift is urgently 
needed - either by stricter federal regulations or improved culture within drug companies that 
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enables enhanced screening of new drugs before they reach the public, or both. Here, we 
propose a solution to address the latter, with the development of a robust and cost effective in 
vitro efficacy and safety assay for improving generic ophthalmic drug screening. 
This project's long-range goal is to improve the efficacy and safety of generic ophthalmic drugs, 
specifically to avert future occurrences of adverse corneal events due to generic formulations 
like the aforementioned diclofenac case. The objective of this report, as the next step towards 
obtaining this goal, is to lay the foundation for the development of a simple, robust and cost 
effective assay that accurately predicts efficacy and safety of new ophthalmic drug 
formulations. The central hypothesis is that drug penetration and epithelial health 
measurements acquired from a single robust in vitro assay, such as the one proposed within, 
will concurrently indicate a generic ophthalmic drug's efficacy and safety, respectively. This 
hypothesis is based upon (1) a review of literature demonstrating the effects of varying 
ophthalmic formulations on corneal penetration, (2) a review of in vivo and in vitro models for 
studying drug penetration into the eye, and (3) a review of techniques for studying and 
quantifying epithelial health. The rationale behind the proposed assay is that by providing a 
rapid, cost effective and robust tool for screening efficacy and toxicity of new ophthalmic 
formulations, drug companies will be better suited to evaluate the bioequivalence and safety of 
generics, resulting in safer generic ophthalmic medications. 
The proposed model, designed to rapidly, robustly, and cost-effectively screen new generic 
formulations, is innovative for these reasons: (1) for the first time drug companies will have a 
4 
FOE ': NFR!C OPHT[ IC I. i<;S 
simple tool for simultaneously assessing generic ophthalmic drug efficacy and safety, and (2) 
robust and rapid in vitro screening will minimize animal testing by identifying comparable drug 
penetration and acceptable corneal health ex vivo, therefore reducing the number of in vivo 
animal studies and animal sacrifices. 
This report aims to accomplish the following: 
(1) emphasize the significance of generic drug formulations, 
(2) elucidate the complexities of drug penetration into the eye, 
(3) review prior art contributing to the design of the proposed model, 
(4) provide a detailed explanation of the model, and 
(5) recommend future work with the proposed model. 
Background and Significance: Generic Ophthalmic Drugs and 
Ocular Drug Delivery 
Recent Generic Ophthalmic Drug Recalls 
The potential risks of generic ophthalmic formulations remain a serious concern among 
ophthalmologist (Jackson, 2010). While cheaper generic ophthalmic medications are attractive 
alternatives to more expensive brand-name drugs, there have been recent cases of drug recalls 
due to reduced generic efficacy and severe corneal damage (e.g., generic diclofenac). These 
recalls highlight the need for better generic screening, but also demonstrate the importance of 
closely monitoring patients if using generic formulations (Gallardo et al., 2006). Examples of 
generic ophthalmic recalls due to reduced efficacy and harmful side effects follow. 
5 
'li\U,11 1 i)RU( 
Prednisolone is an anti-inflammatory steroid commonly used to reduce swelling and irritation 
from eye injury or surgery. In 1999, several lots of the ophthalmic prednisolone formulation 
made by Alcon® Laboratories were recalled because the active ingredient was precipitating out 
of solution and clogging the dropper tip (Fiscella et al, 2001). This issue was easily detected 
because of dropper tip clogging, however slight variations in the suspensions due to 
precipitation or caking can lead to reduced concentrations of the active drug per dose, 
therefore reducing the amount of drug entering the eye. If only a sub-therapeutic level of the 
prednisolone is delivered, inadequate treatment of inflammation is likely. 
A similar case of non-equivalency that led to a recall was with generic ophthalmic timolol. 
Timolol is a ~-blocker indicated for reducing intra ocular pressure (IOP) to slow or prevent the 
progression of glaucoma. Clinicians noticed a trend of increasing IOPs in patients that had 
inadvertently switched to the generic brand, signifying a decrease in the generic drugs efficacy 
for pressure reduction (Weinreb et al., 2003). 
Another generic formulation latanoprost, made by Sun Pharmaceuticals® and indicated for 
reducing IOP, was also recalled due to decreased efficacy as compared to the brand-name 
version. In this case, the formulation was found to have a higher pH than the brand-name, 
which caused a decrease in corneal penetration and decrease efficacy in IOP reduction (Cantor 
et al., 2008). 
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Figure 1: Frequency of Adverse Cornea Events Linked to NSA/0 Use. This histogram show the clear 
correlation between the generic diclofenac (striped bar) and corneal damage as compared to the brand-
name (black bar) and another type of NSAID (white bar). (Used with permission: Congdon et al, 2001) 
As emphasized in the Introduction of this report, a generic formulation of topical diclofenac, a 
nonsteroidal anti-inflammatory drug (NSAID), led to more than 200 cases of severe corneal 
disorders. Severity of these ranged from minor irritation of the corneal epithelium to corneal 
melting, in which epithelial cells slough off the cornea, exposing stroma collagen that then 
rapidly degrades. These severe iatrogenic effects prompted Falcon® Pharmaceuticals to 
immediately withdraw this generic formulation from the market. A study following this recall of 
generic diclofenac found a direct correlation between generic diclofenac use and adverse 
corneal events during the 13 months that the drug was available (Congdon et al, 2001). Figure 
1, above, illustrates this obvious correlations by showing the frequency of corneal pathologies 
due to topical NSAID use from 1994 to 2000. 
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The exact mechanisms of the diclofenac incidents of corneal morbidity were never described, 
but studies following the recall identified the inactive ingredients in the formulation, rather 
than the active diclofenac, as the caused the breakdown of the corneal epithelium and 
subsequent severe corneal damage (Flach, 2000; Congdon et al., 2001). Unfortunately, horrific 
cases similar to the generic diclofenac disaster are probable to reoccur as the FDA is only strictly 
regulating the active ingredients in generic formulations, leaving the inactive ingredients, such 
as buffers and preservatives, unchecked. 
Drug Development Process: Innovative New Drug versus Generic Drug 
Competition from generic drug companies pushes drug costs down and is responsible for 
making previously expensive brand-name drugs more accessible to the public. The U.S. Drug 
Price Competition and Patent Term Act of 1984 (Hatch-Waxman Act) was a significant victory 
for both the consumer and generic drug companies vying to compete with a brand-name drug 
nearing patent expiration (Berndt et al., 2007). The Act specifically prohibits the FDA from 
requiring more than simple bioequivalence studies for generic drugs, expediting and reducing 
the cost of the approval process (Mossinghoff, 1999). Generic drugs are therefore allowed to 
bypass the expensive and time consuming pre-clinical testing and clinical trails that are required 
of innovator drugs. While this abbreviated path to generic drug approval benefits both the 
public (by making drugs cheaper) and the generic drug companies (by reducing testing costs), it 
introduces the regulatory gap that is chiefly responsible for the aforementioned generic 
diclofenac disaster. 
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To better understand the how generic ophthalmic medications have managed to reach the 
marketplace while being dangerous to patients, it is helpful to review the major difference in 
FDA requirements and drug development time and cost between innovative new drugs and 
generic drugs. For innovative new drugs, the FDA requires lengthy and expensive preclinical and 
clinical trials to ensure proper dosage, safety, and efficacy. The development process of a novel 
drug begins with discovery of a new compound and filing of a patent application to protect 
intellectual property. Preclinical testing in vitro and in vivo is completed in the laboratory to 
demonstrate that the new drug is safe enough for human trials, at which point an 
investigational new drug application (IND) is filed with the FDA. If approved, the drug moves 
into a Phase I clinical trial in which toxicity and safety are established in 20 to 50 healthy 
volunteers. Next, a Phase II trial aims to identify how well the drug works and to establish 
proper dosages in a group of 20 to 300 healthy volunteers and patients. If Phase II is successful, 
randomized testing in 300 to 3000 patients to demonstrate efficacy is conducted in the Phase Ill 
trial. If all testing has been successful to this point, the company files a New Drug Application 
(NOA) with the FDA, summarizing the data from the clinical trials. The FDA then decides 
whether to approve of reject the drug (Unger, 2010). This entire process for validating the 
efficacy and safety of the new drug may take as long as seven to 10 years (Mossinghoff, 1999) 
and cost between $500 million and $2 trillion (Adams & Brantner, 2006). 
Alternatively, generic drugs have a much simpler path to approval. Generics are seen by the 
FDA as equivalents to original, innovator drugs, and therefore only require minimal 
bioequivalency testing for approval. No animal testing or full-scale human clinical trials are 
9 
PEl\l:Ti'.ATlO:, ,\NO'.) \iTTY '( FOH Ci:NERt. OP!lTl :,I)]( D res ;, UJZSi ;im 
required as bioequivalency testing is typically performed in a small sample of 24 - 36 healthy 
volunteers to establish comparable pharmacokinetics to the innovator drug. If successful, the 
drug company files an Abbreviated New Drug Application (ANDA) with the FDA. Surprisingly, no 
safety or efficacy testing is required. Systemic generic medications are easily tested for 
bioequivalency by simply measuring drug concentrations in blood and urine following 
administration of the drug. However, measuring generic topical ophthalmic bioequivalence is 
not as easy due to difficulty accessing the aqueous humor. Because non-invasive testing is not 
possible, generic ophthalmic medications are permitted to skip bioequivalency screening as 
long as the active drug is shown to be the same as the innovator (FDA: CFR 21-314, 2010). 
While active drugs must be the same in a generic formulation as the brand-name version, the 
inactive ingredients may vary widely. Essentially, inactive ingredients such as preservatives, pH 
adjusters, antioxidants, thickening agents, buffers, and tonicity adjusters are not regulated 
extensively by the FDA. As the next section will highlight, these 'inactive' ingredients can 
actually play an enormous role in the behavior of topical ophthalmic medications. 
Effects of Formulations on Corneal Penetration 
The non-therapeutic ingredients in topical ophthalmic formulations can significantly modify the 
penetration efficiency of the active ingredient. Formulations may vary in pH adjusters, tonicity, 
preservative content, and other additives between different generic formulations and brand-
name products. 
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As previously mentioned, 13-blockers are commonly indicated in ophthalmology for decreasing 
IOP to slow the progression of or prevent glaucoma. The effect of various formulation additives 
on the penetration of four ophthalmic beta blockers was investigated by Ashton et al. (1991) in 
the cornea and conjunctiva of rabbits. Specifically, the group separately altered the pH, 
osmolarity, benzalkonium chloride and EDTA content of formulations for four 13-blockers, 
atenolol, timolol, levobunolol, and betaxolol, and measured changes in corneal and conjunctiva! 
permeability for each. The results indicated that increasing the pH from 6.0 to 8.4 generally 
increased the penetration of the beta blockers for both the cornea and conjunctiva. Hypotonic 
(83mOsm/kg) formulations were found to predominantly increase corneal penetration and 
slightly increase conjunctiva! penetration of the 13-blockers as compared to isotonic 
(284mOsm/kg) and hypertonic (583mOsm/kg) formulations. Benzalkonium chloride (BAK), a 
preservative, increased conjunctiva! penetration of all four beta blockers, but only improved 
the two least lipophilic 13-blockers. Ethylenediaminetetraacetic acid (EDTA), a commonly used 
chelating agent that acts a preservative, either increased or decreased the corneal and 
conjunctiva! penetration with no correlation to concentration (Ashton et al., 1991). 
Ophthalmic NSAIDs make up a generally safe class of mild analgesia and anti-inflammatory 
drugs indicated for reducing pain and inflammation in the eye. NSAIDs disrupt the synthesis of 
prostaglandin from arachidonic acid by inhibiting cyclooxygenase (COX-1 and COX-2) activity. In 
the eye, prostaglandins lead to vasodilation, increased vascular permeability, pupil constriction 
(miosis), and leakiness in the ocular-blood barrier. Ophthalmic NSAIDs are commonly used to 
maintain pupil dilation (mydriasis) during cataract surgery and have been shown to be very 
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effective in reducing pain and inflammation postoperatively. The high frequency of NSAIDs can 
also be attributed to their minimal adverse side effects as compared to corticosteroids (Nichols 
& Snyder, 1998). Formulations of NSAIDs are of particular interest because of their widespread 
use in ophthalmology, relatively low corneal penetration rate, and also the 1999 generic 
diclofenac dis~ster resulting in more than 200 cases of corneal melts. Corneal permeability has 
been shown to have a high dependency on formulation pH. Most NSAIDs are weak acids, which 
will lower the pH of the tear fluid and lead to decreased solubility (Reer et al., 1994). Reer et al. 
studied pH-adjusted diclofenac formulations and found that a formulation buffered in the pH 
range of 6.5 to 7.0 provided the best corneal penetration. 
Fluoroquinolones are potent, synthetic antibiotics that are frequently used for prophylaxis and 
treatment against bacterial infections in the eye. When formulated as ophthalmic drops, they 
are used perioperatively as prophylaxis against the development of endophthalmitis. Also, 
fluoroquinolones are commonly prescribed to treat bacterial conjunctivitis. A group studied 
how the penetration of gatifloxacin (Zymar®), a newer fluoroquinolone, across the corneal 
changed depending on changes in the pH and preservative content (Rathore & Majumdar, 
2006). Specifically, this group found that gatifloxacin penetrated nearly three times greater 
when optimized at a pH of 6.5, 0.01% (wt/vol) of BAK, and 0.01% (wt/vol) of EDTA. 
In addition to the formulation's effect on penetration, permeability of the active drug across 
the cornea is also largely dependant on the drug's own characteristics. Because of the lipophilic 
nature of most physiological barriers, drug penetration across these membranes relies heavily 
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on the lipophilicity of the drug. However, increasing a drug's penetration across the cornea is 
not as simple as making the drug more lipophilic. Thirty years ago, Schoenwald et al. compared 
the corneal permeability of 11 steroids of varying lipophilicities (defined by their octanol-water 
partition coefficients) and demonstrated a parabolic relationship between corneal permeability 
and octanol-water partition coefficients, as depicted in Figure 2, below (Schoenwald et al., 
1978). 
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Figure 2: Corneal Permeability as a Function of Lipophilicity. This log-log plot relates the permeability 
coefficients of 11 topical ophthalmic steroids to their octanol-water coefficients (larger octanol-water 
coefficient means more lipophilic). It is clear that corneal permeability increases with lipophilicity to a 
point, but then decreases. This parabolic relationship could be due to the lipid-aqueous-lipid nature of the 
cornea's structure (used with permission from: Schoenwald et al, 1978). 
It is clear that additives to topical ophthalmic formulations play a significant role in drug 
penetration of the eye in addition to the active drug's inherent properties such as lipophilicity. 
While formulations can be adjusted to increase drug penetration and half life, additives may 
also introduce an increased risk of damaging the integrity of the corneal epithelium. With new 
generic formulations coming to market that have not been as fully scrutinized as their brand-
name counterparts, there is uncertainty about the combined effects of the active and inactive 
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ingredients on penetration across the cornea and corneal epithelial toxicity. The corneal 
epithelium, which acts as the first line of defense against the penetration of exogenous agents, 
in addition to the other defense mechanisms in the eye that work to suppress drug penetration, 
are explored in the next section. 
Anatomical and Physiological Barriers of the Eye 
The eye is a well-sealed organ. Exogenous agents in systemic circulation are kept from entering 
the eye via the blood-aqueous barrier and the blood-retina barrier, limiting the utility of 
systemically administered therapeutics (i.e., oral or IV) for treating eye pathologies (Urtti, 
2006). This makes topical solutions (eye drops) the principle dosage form for ophthalmic 
therapeutics. The efficacy of an ophthalmic drug, i.e., the maximum therapeutic effect, relies on 
the bioavailability of the drug within the target tissues of the eye. The bioavailability of a drug is 
primarily dependent on its ability to penetrate the efficient barriers of the eye, which is often a 
difficult task. This section reviews the nearly impervious barriers of the eye that restrict 
penetration of topical ophthalmic agents into the eye. 
The most direct route of penetration into the eye is via intra-aqueous or intra-vitreous injection 
(arrow 7, Figure 3, below), in which 100% of the drug reaches either the anterior or posterior 
chamber {100% bioavailability). Direct injection into the eye is not the preferred administration 
method for many reasons, primarily because inserting a needle into the eye weakens epithelial 
integrity exposing the eye to infections. Secondly, intracameral infusions like these are not well 
tolerated by patients as they can be very painful (Olsen et al., 1995). While intra-vitreous 
injection of fluoroquinolone antibiotics may be necessary to access the difficult-to-reach 
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posterior segment in severe cases of endophthalmitis, the preferred route of administration for 
the anterior segment is topical instillation. 
aqueous 
humor 
ciliary body 
corneal epilheliu/ 
conjunclival epithelium 
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sci era choroid 
Routes of Delivery 
Arrow Description 
1 corneal penetration 
2 conj➔scl ➔cilialry 
3 iris blood vessels 
6 RPE➔retina&vitr. 
7 intravitr. injection 
Routes of Elimination 
Arrow Description 
4 aq. humor outflow 
5 iris blood vessels 
8 vitreous➔RPE 
9 vitrous➔aqueous 
Figure 3: Drug Delivery and Barriers in the Eye. This schematic of the eye depicts routes of drug delivery 
into the eye (solid arrows), the barriers that limit entry, and the routes of elimination (dotted arrows). For 
topically instilled ophthalmic drugs, trans-corneal penetration (1) is the most direct route of entry into the 
anterior segment even though drugs must pass through the tight junctions of the corneal epithelium 
(graphic used with permission: Hornof et al., 2005; table created by author). 
The efficiency of the eye's protective barriers reflects the importance of the organ. Rapid tear 
clearance, tight corneal epithelial junctions, and the blood retina barrier (BRB) are always 
working to prevent dirt, microorganisms, and harmful chemicals from penetrating the globe 
and threatening visual acuity. However, in addition to blocking the harmful substances from 
entering, the barriers of the eye also limit entry of pharmaceutical agents. These natural 
barricades can minimize bioavailability of a drug within the globe, potentially leading to sub-
therapeutic drug levels at the target. 
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The eyes are not conveniently located for topical application via drops, as the patient must tip 
their head back to position their eyes before instillation from a dropper bottle. Patients' manual 
dexterity varies widely, which can encumber the proper dosage from entering the tear volume 
due to spill over. Additionally, the natural blinking reflex (activated upon eye drop contact with 
the eye) can block or limit the total volume of the drop from contacting the eye. A typical eye 
dropper dispenses 30 to S0µL of solution per drop and the normal human tear volume (the 
total volume of tear fluid coating the eye) is only 7 to 10µL. Most of the excess volume is nearly 
immediately cleared, leaving behind as little as 5% of the instilled dose. Eye drop instillation will 
also cause increased tear secretion from the lacrimal gland which contributes to the flushing 
away of the drug out the lacrimal canal and down the nasolacrimal duct. Under normal 
physiological conditions, tears turnover at a rate of 16% per minute, which means nearly the 
entire dose is cleared from the surface of the eye within 5 minutes (Chrai et al, 1973). Drug 
penetration into the eye, which dictates a drug's therapeutic effect, principally depends on 
contact time with the cornea, meaning the rapidly diminishing drug concentration in the tear 
volume only has a narrow time-window to enter the eye. 
The ultimate destination of topical ophthalmic drugs is the anterior chamber from which a drug 
has direct access to eye's anterior tissues that contact the aqueous humor (see Figure 3, 
above). While the cornea is the primary route of entry into the anterior segment, it acts 
predominantly as a barrier to drug diffusion and is considered the rate-limiting structure for 
drug absorption (Mitra, 2003). The cornea is a three-layered, S00µm thick transparent lens that 
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provides nearly 75% of the eye's refractive power. Five epithelial cell layers make up the 
anterior stratum of the cornea with the primary function of protecting the integrity of the 
cornea as any imperfection could reduce transparency and impede vision. The entire 
epithelium is S0µm thick and highly lipophilic, with zonulae occludentes (tight junctions) 
between cells that house pores no bigger than 60A, effectively keeping out large and/or 
hydrophilic molecules. The integrity of the tight junctions, which can be quantified by 
measuring trans-epithelial resistance, is typically 12-16 kohm-cm2, thwarting penetration of 
most compounds. The primary pathway for drug penetration through the epithelium is 
diffusion across the cell membranes, relying on drug-epithelial contact time, diffusivity, and 
cornea surface area of the (Mitra, 2003). 
Once across the corneal epithelium, the drug molecules reach the highly hydrophilic, 450µm 
thick stroma layer consisting of approximately 200 lamell<E of hydrated collagen. Because this 
layer is primarily acellular (except sporadic keratocytes), it is mostly hydrophilic and lacks the 
tight junctions of the epithelium. Therefore, the stroma is more passable to hydrophilic drugs 
but less so to lipophilic molecules. 
A penetrating drug will next hit the corneal endothelium, which is a single, 4 to 6 µm layer of 
squamous cells as the final barrier to the anterior chamber. The endothelium's primary role is 
to maintain the health and transparency of the avascular stroma with densely packed ion 
pumps and channels and aquaporins that work to move solutes and nutrients from the aqueous 
humor into the stroma while pumping water from the stroma to the aqueous humor (Verkman, 
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2008}. While the endothelial cells' lipid membranes make this barrier lipophilic in nature, 
permeability has been found to rely primarily on molecular weight of a solute, allowing 
molecules under 70kDa to easily pass. Most topical ophthalmic drugs are small molecules of 
around 300 to S00Da (about 200 times less than the maximum}, rendering the corneal 
endothelium highly porous to these compounds. 
While the cornea is the primary route of drug penetration into the eye, it is not the only 
pathway (Ahmed & Patton, 1985}. The remainder of the non-cornea surface of the eye is 
covered by conjunctiva, a three-layered, protective membrane that covers 17 to 20 times more 
surface area than the cornea (Mitra, 2003}. The conjunctiva extends from the perimeter of the 
cornea covering the white of the eye (sclera} and continuously wraps around to coat the insides 
of the eyelids. Even with 20 times more surface area, conjunctiva! penetration into the anterior 
segment is poor due to proximity to the anterior chamber (arrow 2, Figure 3}, and structure. 
Like the cornea, the conjunctiva carries a protective epithelial layer as its first line of defense. 
While not as robust as the cornea's epithelium {1.4 kohm-cm 2 vs. 12-16 kohm-cm2}, the 
conjunctiva! epithelium is effective in keeping most exogenous substances out. Below the 
conjunctiva! epithelium is the substantia propria, a layer filled with nerves, blood vessels and 
lymphatic vessels. Here, drug concentration faces major losses because of clearance to the 
blood stream or lymphatics. 
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Beneath the conjunctiva lies the sclera, which is made up primarily of irregularly structured 
collagen and elastin, providing the eye's white color. The sclera's primary inhibitor of drug 
penetration is its thickness, which ranges from 0.3 to 1.0mm (Olsen et al., 1995). 
On a sub-cellular level, membranes of the epithelial cells of the cornea and conjunctiva house 
ion channels, exchangers, and transporters, aquaporins, and efflux pumps that can affect drug 
penetration. These trans-membrane proteins work together to keep the eye's tissues healthy, 
however they also play a significant role in the penetration kinetics of ophthalmic drugs. 
Specifically, ion pumps and channels are influence the movement of hydrophilic drugs based on 
their influence on water movement (Mitra, 2003). Efflux pumps, which are large proteins 
responsible for exporting exogenous agents, can move anionic and lipophilic drugs out of the 
eye (Karla et al., 2009). 
Systemic delivery of drugs to the anterior segment is possible, but is relatively ineffective. As 
depicted in Figure 3, there is some transfer of drugs from systemic circulation into the anterior 
chamber via diffusion from blood vessels in the iris; however this is minimal (Hornof et al., 
2005). Even with the effective corneal barriers, trans-corneal penetration remains the most 
direct path for topical ophthalmic drugs to the aqueous humor. 
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Figure 4: Compartmental Models of the Eye. These block diagrams show typical pathways for a topically 
instilled ophthalmic medication and help explain a drug's pharmacokinetics. It is obvious that the major 
rate-limiting step in ocular drug delivery is drug loss from the tear volume (Used with permission: Worakul 
& Robinson, 1997). 
The pharmacokinetics of a drug helps describe how and where a drug moves within the body 
after administration. This includes drug absorption, distribution, metabolism and excretion 
(ADME) from the body, which together describe how the body acts upon the drug. For 
intravenous and orally administered drugs, which are distributed via systemically, the rate 
limiting step is typically metabolism, or how fast the active drug is broken down into inactive 
metabolites. Alternatively, for topically instilled ophthalmic drugs which are distributed via the 
aqueous humor, the rate limiting step is absorption, from the tear volume across the cornea 
and into the anterior chamber. Compartmental models are often employed to explain the 
pharmacokinetics of ophthalmic drugs (Worakul & Robinson, 1997; Sakanaka et al., 2008). For 
IV or oral drugs, two-compartment models typically include the blood volume and the target 
tissue as the compartments with rate constants (denoted as k) to describe movement of the 
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drug into or out of each compartment. Pharmacokinetic models, such as those shown in Figure 
4 (above), help identify the variables to adjust in order to improve the penetration and 
bioavailability of a drug within the eye. For the in vitro model proposed in this report, the 
following compartments will be relevant: tear volume, cornea, and aqueous humor. 
The pharmacodynamics of a drug helps describe how the drug interacts within the body to 
cause a therapeutic effect. The efficacy and potency of a drug can be extrapolated from dose-
response curves which are generated by measuring a physiological response due to a given 
concentration of a drug. Such studies lend themselves primarily to in vivo testing where 
response can be directly measured (e.g. - extent of pupil dilation for mydriatic NSAIDs or IOP 
decrease for ~-blockers). The proposed model will not be aimed at understanding the 
pharmacodynamics of generic drugs, but it is important to also consider how a drug will behave 
beyond corneal penetration. 
Designing an In Vitro Model of the Cornea 
An in vitro model of the cornea can provide valuable preliminary information about the effects 
of a drug composition or formulation on corneal penetration and toxicity. Many groups have 
studied corneal permeability to various drugs and formulations in both in vivo (Eremeev et al., 
2006; Puustjarvi et al., 2006) and in vitro models (Burgalassi et al., 2004; Gratieri et al., 2010; 
Martfn-Biosca et al., 2003) but few groups have attempted to better understand corneal 
epithelial toxicity (Dart, 2003). Currently, the published literature indicates that no research 
group is actively pursuing an in vitro model to study both corneal penetration and toxicity op 
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topical ophthalmic drugs in parallel. This section will review past and current research relevant 
to the development of the proposed penetration and toxicity model. The first goal, as an 
important step towards success of the model, is to demonstrate validity and robustness of 
model's ability to predict drug penetration. Once this has been accomplished, the model will 
then be expanded to meet the second goal of predicting drug toxicity. To help narrow the 
engineering design of the model, prior art was examined to identify the optimal techniques for 
testing corneal penetration and toxicity. The following subsections review literature to identify 
and describe the major components of the assay. 
Assay's Design Criteria 
Key engineering design criteria to consider while designing this penetration and safety assay for 
topical ophthalmic formulations include: physiological relevance (do the in vitro result 
accurately predict in vivo behavior?), robustness/reproducibility (does the assay provide 
accurate results with different users?}, and cost effectiveness (is the assay cheap enough for 
drug companies to adopt into their research and development?). The ultimate goal of this 
research project is to design and assemble a robust, in vitro assay for studying (1) the 
penetration mechanisms and (2) the toxicity of ophthalmic therapeutics when applied topically 
to a model cornea. Based on a literature review of prior art, the following design features are 
important to consider for our model's design: 
• Cornea substrate 
• Diffusion chamber hardware 
• Penetration measurement system 
• Health and toxicity measurement system 
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This ultimate success of this proposed assay will be based on its ability to accurately and 
precisely predict satisfactory drug penetration and safety of topical ophthalmic drugs. While the 
assay's purpose is not to specifically identify exact pharmacokinetics or toxicity, it will provide 
researchers a 'go' or 'no-go' result that raises red-flags on potentially toxic formulations. As 
with any in vitro model, results must be later be confirmed with in vivo testing, however first-
pass in vitro as performed by this model will significantly reduce the number of animals used. 
Validation of the model's accuracy and precision for identifying acceptable penetration rates 
and toxicity levels will be essential before implementation. 
Corneal Substrate Selection 
The key element to the proposed penetration and toxicity assay is the cornea substrate. While 
the most physiologically relevant corneal penetration models are in vivo, these live animal 
assays are very costly and not ideal quickly for a screening large numbers of compounds. 
Additionally, using live animals raises ethical questions that are circumvented by using in vitro 
surrogates. Therefore, due to the cost, time and ethical considerations the optimal cornea 
substrate for the proposed model must be in vitro. 
Non-rodent in vivo animal models are typically closest substitute for human trials, but 
anatomical differences should be noted. For example, rabbits are commonly used as the animal 
model of choice for ophthalmic drug penetration and toxicity studies due to their large globe 
size while being a smaller and less expensive than using dogs or monkeys. However, anatomical 
differences are significant among species - rabbit anterior segment anatomy is vastly different 
than primates, which are closest in resemblance to humans (Short, 2008}. Major differences 
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between rabbit and human eyes include (rabbit vs. human) cornea surface area (2.0cm2 vs. 
1.4cm2), cornea thickness (0.40mm vs. 0.50mm), and aqueous humor volume (0.25-0.3ml vs. 
0.1-0.25ml) (Worakul & Robinson, 1997). 
Many research groups have attempted in vitro epithelial cell culture as an alternative to using 
live animals, such as rabbits, for penetration studies (Burgalassi et al., 2004; Toropainen et al., 
2001). The most significant advantages of cell culture models are their low cost and that they 
do not require the sacrifice of animals (Burgalassi et al., 2004). However, these models have 
inherent deficiencies in that re-growing epithelial tight junctions to their normal physiological 
integrity is extremely difficult (Hornoff et al., 2005). Penetration results from epithelial cell 
culture models like these may be physiologically irrelevant because the epithelial tight 
junctions, the rate limiting barrier to penetration, are deficient. While recent improvements in 
cell culture models are promising, the closest in vitro surrogates to in vivo models are live, 
excised cornea with intact epithelium (Burgalassi et al., 2004). 
Human cadaver corneas are not commonly used for penetration studies because of cost and 
difficulty of obtaining specimens with the corneal epithelial layer still alive. Therefore, excised 
animal corneas are ideal substitutes. Many groups have been successful using trephinated 
corneas from excised rabbit eyes (Valls et al., 2008) and pig eyes (Gratieri et al., 2010) to study 
ophthalmic drug penetration. Porcine eyes are typically discarded from slaughterhouses, 
making this a cheap and quickly obtainable tissue source for the proposed model. 
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Considering the various experimental models for corneal penetration studies reviewed above, 
the ideal surrogate for this assay is an excised porcine cornea. As pigs are ubiquitously raised 
and slaughtered for human consumption, discarded tissue, specifically the eyes, is readily 
available. Because drug penetration relies heavily on corneal epithelial health, it will be 
important to obtain the discarded eyes as quickly as possibly following animal death, meaning 
research laboratory proximity to slaughterhouse is critical. For the scope of the proposed study, 
the University of Arizona houses a Meat Sciences laboratory that slaughters pigs weekly, 
meaning direct access to live cornea tissue is achievable. 
Additionally, it may be preferable to find an alternative to live animal cornea to reduce the 
assay's dependence on proximity to a slaughterhouse and/or availability of tissue discards. 
Potential solutions could include a robust cell cultured or synthetic surrogate of the cornea and 
should be explored (Mina mi et al., 1993}. 
Hardware Considerations 
Following the cornea substrate, the second-most critical aspect of the model is the diffusion cell 
hardware, in which the trephinated cornea will be affixed to define two separate chambers. 
Primary considerations for hardware selection include validity of experimental setup 
(physiological relevance} and scalability (cost, reproducibility, ease of use). 
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Figure 5: Diffusion Chamber Hardware Options: (A) Ussing Chamber (Used with permission: Li et al., 
2004). (BJ Snapwe/1 (Used with permission: Hornoff et al., 2005). (CJ Franz Cell (drawn by author). These 
schematics depict three diffusion cells that have been used for corneal permeability testing (not to scale). 
Arrows point to the location of the cornea substrate for each apparatus. 
In reviewing the literature describing drug penetration studies of the cornea, most groups used 
either an Ussing chamber (Ashton et al., 1991; Li et al., 2004), a Franz cell (Resch et al., 2010; 
Gratieri et al., 2010), or Snapwell plates (Burgalassi et al., 2004) as diffusion cell hardware as 
depicted in Figure 8, above. Each apparatus has advantages and disadvantages as compared to 
the others, such as cost, ease of use and physiological relevance, which are important factors in 
designing the proposed penetration and toxicity assay. 
Li et al. (2004) describes how Ussing chambers can be used to measure trans-epithelial 
resistance during penetration studies to monitor epithelial tight junction integrity. A major 
disadvantage of an Ussing chambers is that they can be costly to set up due to the complexity 
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of glassware, chambers and equipment. Also, the Ussing chamber submerges both the 
epithelial and endothelial sides of the cornea in solution, making it difficult to administer test 
formulations and to access the epithelial layer for monitoring epithelial health. 
Other groups have even used a very simple setup when examining cell-cultured epithelia layers 
with use of Snapwell plates (Burgalassi et al., 2004). Here, rabbit epithelial cells were grown on 
a porous support at the bottom of a small diameter well which was slightly submerged into a 
larger diameter well containing media, therefore separating the donor and acceptor chambers. 
An advantage of this diffusion cell over the other models is the multi-well design, allowing 12 or 
24 simultaneous experiments while the Ussing chamber and Franz cell only accommodate a 
single experiment. While simple to use and cheap, the Snapwell plate lends itself specifically to 
cell culture models, and is therefore unacceptable for the proposed model due to the 
aforementioned reasons. 
Gratieri et al. (2010) used a modified Franz cell to study as the basis for a model of excised 
porcine cornea for iontophoresis-enhanced penetration studies. The major advantages of a the 
Franz cell are cost, ease of use, and an air-substrate interface that more closely resemble 
physical conditions of the cornea. This setup is ideal for topical administration of test 
formulations and access to the corneal for epithelial health monitoring. 
Major advantages of the Snapwell plate and Franz cell are low cost, physiological relevance, and 
ease of use as compared to the more expensive Ussing chamber. While the Ussing chamber 
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submerges both sides of the cornea, the Franz cell leaves an air-cornea interface on the 
epithelial side. The Franz cell is the preferred apparatus for the proposed model because of cost 
($100s vs. $1000s), physiological relevance (air-epithelial interface vs. aqueous-epithelial 
interface), substrate compatibility (excised cornea tissue vs. cell culture), and access to the 
epithelial surface for toxicity monitoring. 
Penetration Measurements 
The first goal in assembling the proposed in vitro model is to validate corneal permeability. 
Simply, samples from the acceptor chamber of the diffusion cell can be sampled and analyzed 
for drug concentrations for the duration of an experiment. This data can then be used to 
calculate either the drug penetration rate or apparent permeability coefficient. The key to the 
precision and accuracy of penetration measurements is the sensitivity of the drug 
concentration measurement system. 
One promising and fairly simple method for measuring drug penetration, as long as the 
sensitivity is shown to be adequate, is with a spectrophotometer. First, the wavelength at which 
the drug molecule absorbs the greatest should be identified. This is simply done by placing a 
small aliquot of high concentration drug solution into a cuvette and measuring its absorbance 
across the entire spectrum from ultraviolet to infrared light. The wavelength at which the drug 
absorbs the greatest is then selected and used to quantify concentration. Then, a set of 
concentration standards can be made by diluting the original drug solution into aliquots 
covering a range of known concentrations. By measuring the percentage of light absorption of 
each known standard at the previously identified wavelength, a linear relationship between 
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light absorption and drug concentration is obtained. This calibration curve is then used to 
extrapolate drug concentrations based on absorption data from experimental samples. Resch et 
al. (2010} used this straightforward method for quantifying ofloxacin concentration during a 
penetration study of amniotic membrane. Variations of this spectrophotometer method have 
demonstrated good precision and accuracy down to concentrations of 0.Sµg/ml (Kanakapura & 
Rangachar, 2007). 
A more sensitive and more expensive method for measuring concentration of a compound is 
via high performance liquid chromatography (HPLC). Santoro et al. (2006) demonstrated 
precision, accuracy and sensitivity of using HPLC to quantify concentrations of fluoroquinolone 
antibiotics down to 4.0µg/ml. In measuring beta blocker concentrations with HPLC, Aston et al. 
(1991) claimed a detection limit down to Sng/ml (0.00Sµg/mL), which is 100 times more 
sensitive than the most sensitive spectrophotometric method. 
The sensitivity of the concentration measurements is critical for the validity of this in vitro 
model. If the detection limit of the measurement system is too high, it would be impossible to 
accurately determine small changes in penetration rates due to changes in formulations, which 
is a critical aspect of the proposed assay. While sensitivity considerations point towards HPLC as 
the preferred measurements systems, cost and ease of use is also a factor which make 
spectrophotometry an attractive method also. 
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Corneal Health and Toxicity Measurement 
Alternatives to toxicity screening in live animals are desirable (Herzinger et al., 1995). In 
developing new topical ophthalmics, the Draize test (which has been used since the 1940s) is 
often employed to screen for potential toxicity in rabbits (Dart, 2003). In this test, the new drug 
formulation is applied to rabbits' eyes, and over the next 14 days the rabbits are observed for 
changes in corneal opacity, iris inflammation, conjunctiva! redness, chemosis, and discharge to 
identify toxicity. At the conclusions of the test, the rabbits are typically euthanized. While this 
method is effective in screening for immediate and severe toxicity, it does not serve utility to 
identify the subtle changes in epithelial health that could indicate potential epithelial sloughing 
or corneal melts (like the generic diclofenac case). Alternatively, an in vitro assay, like the one 
proposed here, could provide a more precise method for monitoring slight changes in corneal 
health. Additionally, an in vitro assay would not require the sacrifice of animals for toxicity 
studies and could therefore be more ethical and less expensive. 
The effect of the drug on epithelial health is a critical element of the proposed model, as 
breakdown of this protective barrier can be catastrophic for the health of the cornea. It will be 
essential to not simply identify whether the drugs kill the epithelial cells, but to monitor small 
changes in cell health over the duration of the experiment, which is significantly more complex. 
Changes in epithelial metabolic activity is a good indicator of a changes in cell health, meaning 
measuring concentrations of metabolic compounds like NADH or ATP could be used. 
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Among the few groups that do study corneal epithelial toxicity, most of these use cell culture 
models as their substrate {Dart, 2003; Geerling et al., 2001; Poon et al., 2001). These techniques 
are typically endpoint assays, ending in cell sacrifice and meaning these techniques would not 
be suitable for non-invasively monitoring cell health. In studying the toxicity of tear substitutes 
on epithelial cells, Geerling et al. {2001) used cultured human corneal epithelial cells in vitro to 
assess toxicity due to varying concentrations as compared to control in a viability assay and an 
ATP assay. The viability assay simply used fluorescent live-dead staining and by counting live 
and dead cells. The ATP assay used a luminescence technique to determine cellular ATP content 
{Geerling et al., 2001). Poon et al. (2001) also used these techniques to evaluate toxicity of 
serum eyedrops in vitro on a cell cultured epithelial model. 
While viability assays and ATP assays are effective endpoint indicators of toxicity in cell culture, 
these techniques would not be suitable for our model. Specifically, to monitor the health of 
excised cornea throughout the course of an experiment, a non-invasive technique will be 
needed. 
To avoid the problems of the endpoints assays described above, a significantly more complex 
method for determining cell health is to monitor the concentration of NADH in the corneal 
epithelial layer, which is typically 45 µm thick consisting of five cell layers. Measurement of 
NADH levels can be indicative of the metabolic activity of the cells and therefore health. Piston 
et al. demonstrated a two-photon microscopy method for measuring changes in NADH 
autofluorescence due to epithelial poisoning from cyanide {Piston et al., 1995). A simpler 
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microscopy method could instead target changes in the regular hexagonal cell structure of the 
squamous cells that make up the outermost epithelial cell layer. Changes in squamous cell 
morphology could indicate toxicity (Dart, 2003}. 
Trans-epithelial resistance is often measured in penetration studies to monitor the integrity 
epithelial tight junctions during penetration studies (Toropainen et al., 2001; Li et al., 2004}. In 
this simple, non-imaging technique, electrical resistance across the cornea can be monitored 
with electrodes on either side of the membrane. By applying a known voltage (V} and 
measuring the changes in current (/}, the resistance (R} is calculated using Ohm's Law: R = V . 
I 
Alternatively, resistance can also be measured by inputting a known current and measuring 
change in voltage. Larger resistances indicate tighter junctions between epithelial cells and 
smaller resistances indicate looser junctions. While this method is easy to use, it may not 
provide information sensitive enough to correlate changes in resistance to epithelial toxicity 
and will need to be explored. 
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3. Aqueous humor surrogate (tbd) 
4. Drug concentration quantification (spectrophotometry or HPLC) 
5. Epithelial health quantification (tbd) 
As seen in Figure 6, above, the proposed model consists of a modified Franz cell housing a 
trephinated porcine cornea. The cornea is clamped between the spherical surfaces of the donor 
and acceptor chambers with the epithelial side exposed. The acceptor chamber is filled with the 
surrogate aqueous humor (contacting the endothelial side of the cornea) homogenized with a 
magnetic stir bar and the warm water jacket is supplied by a heat bath at 37°C. After applying 
the drug formulation to the epithelial surface, samples of from the acceptor chamber are 
obtained over the duration of the experiment to determine the drug flux across the cornea. 
The apparent permeability coefficient (Papp), in cm/min, is the most frequently used term for 
representing a drug's permeability through the cornea. This coefficient can be calculated 
with: P = aQ , where 60/ot is the permeation rate (mol/sec), SA is the surface area 
arp atSAC 
0 
(cm2), and Co is the initial concentration (mol/ml) in the donor compartment (Valls et al., 2008). 
The permeation rate (60/ot) is determined by the concentration-time curve generated by 
measuring the amount of drug penetrating the cornea over time. 
The diameter of the diffusion cell's orifice will determine the exposed surface area (SA) of the 
cornea through which test drugs will permeate. For example, with an outer corneal radius (r) of 
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6mm, and an orifice radius (a} of 2.5mm, the total surface area of the exposed corneal 'dome' 
will be: SA= 2nr~ --Jr 2 - a 2 ), which comes to 0.206cm2• The typical surface of a human 
cornea is 1.04cm2 (Worakul & Robinson, 1997}, meaning the model will represent 20% of a 
human cornea and should be considered when interpreting data. 
The anterior chamber of the human eye typically houses 0.1 to 0.25ml of aqueous humor 
(Worakul & Robinson, 1997). The model's acceptor chamber, which represents the anterior 
segment of the eye, is 5ml in the current design, meaning the volume will be 20 to 50 times 
larger. This will only present a problem if the drug concentration measurement system 
(spectrophotometer or HPLC} is not sensitive enough to detect small concentrations. A simple 
modification can be made to reduce this volume if better sensitivity is needed. 
Histology can be used to confirm the epithelial integrity after experimentation, but trans-
epithelial resistance can be monitored to indicate changes in the tight junction integrity. 
Resistance can be measured by placing an electrode on either side of the cornea, as previously 
described. Consistent corneal thickness for the duration of an experiment demonstrates the 
health of the endothelial cells, which regulate the corneal stroma hydration. A pechymeter, 
which is used clinical for cornea thickness measurements, can be used to for corneal thickness 
monitoring. 
To mimic the aqueous humor, many groups use a buffer that simulates the physiological 
constituents of aqueous humor (Valls et al., 2008; Burgalassi et al., 2004; Toropainen et al., 
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2001}. Specifically groups have used glutathione bicarbonate Ringer solution at a pH 6.5 
(Burgalassi et al., 2004}, artificial tear solution with added glutathione (0.13g/L} and adenosine 
(0.09g/L) (Valls et al., 2008}, balanced salt solution (Toropainen et al., 2001), and 2SmM HEPES 
buffer solution (Gratieri et al. 2010). For the proposed model, these will have to be evaluated to 
identify which keeps the excised cornea healthiest for the duration of testing (4 to 6 hours} 
while not interfering with the absorption spectra (concentration measurements) of tested 
drugs. 
The proposed model will be successful if it meets the following criteria: 
• Predictive of corneal penetration 
• Predictive of epithelial health 
• Robust and reproducible 
• Cost effective 
As with any in vitro model, in vivo testing will still need to be completed to confirm the validity 
of the in vitro results. Since the goal of the proposed assay is to weed out as many insufficiently 
penetrating or toxic formulations in vitro, the number animals used for testing will be 
minimized. 
Conclusion 
The development of a simple, robust, and cost effecting assay for enhanced screening of 
ophthalmic generics is urgently needed. The reviewed literature points towards the feasibility 
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of assembling such a model that can robustly screen ophthalmics for penetration and safety. 
The gap in FDA regulation of generic ophthalmic formulations places the public at unnecessary 
risk, which could be alleviated if drug companies self-imposed stricter research and 
development methods. However, because drug companies are businesses and must make 
money to survive, the only way for non-FDA required screening to be implemented is to make 
the proposed assay cost effective. 
The novelty of the proposed model is its ability to simultaneously evaluate penetration and 
toxicity of topical ophthalmic formulations, which, based upon a thorough literature review, has 
not been previously demonstrated. Many groups have assembled ocular penetration models 
for the purpose of better understanding and improving penetration kinetics into the eye and 
some groups have even developed methods to quantify epithelial health. By combining the best 
qualities of these two methods, the proposed model will be a powerful tool for rapidly 
screening new ophthalmic formulations, resulting in reduced animal studies and safer and more 
efficacious drugs. Additionally, if the proposed model proves to be successful in predicting 
penetration and safety of generic ophthalmic formulations, it is likely to also serve utility as a 
tool for screening novel formulations in pre-clinical testing in addition to generic formulations. 
The logical next step the project's progression is to identify specific aims for researching drug 
penetration and toxicity with the proposed model as part of the author's future Ph.D. work. 
Future specific aims could include: 
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Specific Aim 1: Evaluate the differences in corneal penetration between commercially available 
brand-name and generic topical ophthalmic medications. 
Working Hypothesis: Variations between additives in brand-name and generic 
formulations alter drug penetration kinetics, resulting in varying efficacy. 
Specific Aim 2: Develop a sensitive measurement system for quantifying subtle changes in 
epithelial health that are precursors to corneal toxicity. 
Working Hypothesis: Minor variations in mitochondrial NADH levels or squamous cell 
morphology are indicative of corneal toxicity. 
Even after validating the model for accuracy in predicting a the penetration and toxicity of a 
generic formulation, the success of the proposed assay will ultimately be determined by drug 
companies' willingness to adopt an extra layer of screening that is not required by the FDA. 
Predominantly, the assay must be cost effective for drug companies to subscribe to this extra 
research expense. Arguments in support of the assay's cost effectiveness could include the (1) 
reduction of costly animals testing and (2) reduced risk of costly drug recalls. The current 
rendition of the assay as depicted and described within this report, may not be the least 
expensive incarnation of the assay due to the need for live excised porcine corneas and single-
run hardware, so future modifications will have to be made. 
As ophthalmic NSAIDs, fluoroquinolones, and ~-blockers come off patent protection in the 
coming years, many generic formulations will be vying to compete for market share. If efficacy 
and safety screening of generic ophthalmic drugs does not improve soon, repeats of the 1999 
38 
,\ND TY /\~c;/\y FOH ,; NERIC ClP!ITI!,\ 
diclofenac disaster are possible. Implementation of an efficacy and safety assay, like the one 
proposed in this report, into the screening process of generic ophthalmic drugs will eliminate 
uncertainty and protect the public's health. 
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